EA202193190A1 - Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов - Google Patents

Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов

Info

Publication number
EA202193190A1
EA202193190A1 EA202193190A EA202193190A EA202193190A1 EA 202193190 A1 EA202193190 A1 EA 202193190A1 EA 202193190 A EA202193190 A EA 202193190A EA 202193190 A EA202193190 A EA 202193190A EA 202193190 A1 EA202193190 A1 EA 202193190A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pridopidine
huntington
symptoms
disease
analogue
Prior art date
Application number
EA202193190A
Other languages
English (en)
Inventor
Михал Гева
Елена Берелович
Майкл Хайден
Original Assignee
Прилиния Ньюротерапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/438,508 external-priority patent/US11090297B2/en
Application filed by Прилиния Ньюротерапьютикс Лтд. filed Critical Прилиния Ньюротерапьютикс Лтд.
Publication of EA202193190A1 publication Critical patent/EA202193190A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Изобретение относится к способу лечения пациента-человека, страдающего болезнью Гентингтона и/или ее симптомами, включающему введение пациенту фармацевтической композиции, включающей придопидин или его фармацевтически приемлемую соль и его аналог или его фармацевтически приемлемую соль.
EA202193190A 2019-06-12 2020-06-12 Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов EA202193190A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/438,508 US11090297B2 (en) 2013-06-21 2019-06-12 Pridopidine for treating huntington's disease
PCT/IL2020/050654 WO2020250234A1 (en) 2019-06-12 2020-06-12 Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof

Publications (1)

Publication Number Publication Date
EA202193190A1 true EA202193190A1 (ru) 2022-03-24

Family

ID=73782137

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193190A EA202193190A1 (ru) 2019-06-12 2020-06-12 Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов

Country Status (11)

Country Link
EP (1) EP3982963A4 (ru)
JP (2) JP7436524B2 (ru)
CN (1) CN113950328A (ru)
AU (1) AU2020293739B2 (ru)
BR (1) BR112021024744A2 (ru)
CA (1) CA3137633A1 (ru)
CL (1) CL2021003312A1 (ru)
EA (1) EA202193190A1 (ru)
IL (1) IL288940A (ru)
MX (1) MX2021015338A (ru)
WO (1) WO2020250234A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192542A1 (en) * 2020-10-20 2022-04-28 Michael Hayden Use of pridopidine and analogs for the treatment of anxiety and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US9012476B2 (en) * 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015017307A (es) * 2013-06-21 2016-08-03 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP6912574B2 (ja) * 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用

Also Published As

Publication number Publication date
CL2021003312A1 (es) 2022-08-26
CA3137633A1 (en) 2020-12-17
MX2021015338A (es) 2022-01-18
WO2020250234A1 (en) 2020-12-17
AU2020293739A1 (en) 2021-12-16
JP2022535929A (ja) 2022-08-10
CN113950328A (zh) 2022-01-18
AU2020293739B2 (en) 2023-11-30
EP3982963A4 (en) 2023-06-21
IL288940A (en) 2022-02-01
EP3982963A1 (en) 2022-04-20
BR112021024744A2 (pt) 2022-03-22
JP2024016113A (ja) 2024-02-06
JP7436524B2 (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
ME02414B (me) Tretman kronove bolesti lakvinimodom
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
CL2022000786A1 (es) Metodos de tratamiento para modificar la hemodinamica
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
BR112022017998A2 (pt) Formulações de liberação controlada compreendendo drotaverina ou sal da mesma
JP2019529569A5 (ru)
MX2021012579A (es) Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos.
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
EP3919052A4 (en) PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAR DISEASES
RU2005131578A (ru) Аплидин для лечения множественной миеломы
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele